List of Zilretta drug patents

Zilretta is owned by Pacira Pharms Inc.

Zilretta contains Triamcinolone Acetonide.

Zilretta has a total of 2 drug patents out of which 0 drug patents have expired.

Zilretta was authorised for market use on 06 October, 2017.

Zilretta is available in for suspension, extended release;intra-articular dosage forms.

Zilretta can be used as method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide.

The generics of Zilretta are possible to be released after 04 August, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555048 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(8 years from now)

US8828440 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(8 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 06 October, 2017

Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic